Pariket M Dubal1, Aykut A Unsal2, Kristen A Echanique1, Alejandro Vazquez1, Lindsay S Reder3, Soly Baredes1,4, Jean Anderson Eloy1,4,5,6. 1. Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey. 2. Department of Otolaryngology & Facial Plastic Surgery, Rowan University School of Osteopathic Medicine, Stratford, New Jersey. 3. Department of Otolaryngology-Head and Neck Surgery, University of Southern California, Los Angeles, California. 4. Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey, Rutgers New Jersey Medical School, Newark, New Jersey. 5. Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey. 6. Department of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: Adenosquamous carcinoma (ASC) is a rare entity, with fewer than 100 cases having been reported in the upper aerodigestive tract. Thus, no large samples characterizing its clinical behavior are available in the literature. Investigation of ASC has been further limited by difficulty in establishing histopathologic diagnosis. Our objective was to use a national population-based resource to evaluate patient demographics, clinical behavior, incidence, and survival for laryngeal adenosquamous carcinoma (LASC). STUDY DESIGN: Retrospective population-based analysis. METHODS: The National Cancer Institute's Surveillance, Epidemiology, and End Results database was used to search for patients diagnosed with LASC between 1973 and 2012. Patient demographics, tumor characteristics, incidence, and survival trends were analyzed. RESULTS: Of the 68 identified LASC patients, 79.4% were male and 20.6% were female. The mean age at diagnosis was 66.0 ± 10.8 years. Whites represented 80.9% of patients, but no racial predominance was noted. LASC most commonly affected the glottis (47.1%), followed closely by the supraglottis (42.6%). Most cases were poorly differentiated (59.2%) and presented with stage IV disease (40.7%). Metastasis (M1) was noted in 10.7% of cases. The overall incidence was 0.003/100,000. The 5-year disease-specific survival rate was 36.6%, with a median observed survival of 33.6 months. CONCLUSIONS: This study notes that LASC has low overall incidence. It has a predilection for males, but does not demonstrate racial predominance. LASC tends to present with stage IV disease, with distant metastasis noted in approximately one in 10 cases. Overall prognosis is poor, with a median survival under 3 years. LEVEL OF EVIDENCE: 4.
OBJECTIVES/HYPOTHESIS: Adenosquamous carcinoma (ASC) is a rare entity, with fewer than 100 cases having been reported in the upper aerodigestive tract. Thus, no large samples characterizing its clinical behavior are available in the literature. Investigation of ASC has been further limited by difficulty in establishing histopathologic diagnosis. Our objective was to use a national population-based resource to evaluate patient demographics, clinical behavior, incidence, and survival for laryngeal adenosquamous carcinoma (LASC). STUDY DESIGN: Retrospective population-based analysis. METHODS: The National Cancer Institute's Surveillance, Epidemiology, and End Results database was used to search for patients diagnosed with LASC between 1973 and 2012. Patient demographics, tumor characteristics, incidence, and survival trends were analyzed. RESULTS: Of the 68 identified LASCpatients, 79.4% were male and 20.6% were female. The mean age at diagnosis was 66.0 ± 10.8 years. Whites represented 80.9% of patients, but no racial predominance was noted. LASC most commonly affected the glottis (47.1%), followed closely by the supraglottis (42.6%). Most cases were poorly differentiated (59.2%) and presented with stage IV disease (40.7%). Metastasis (M1) was noted in 10.7% of cases. The overall incidence was 0.003/100,000. The 5-year disease-specific survival rate was 36.6%, with a median observed survival of 33.6 months. CONCLUSIONS: This study notes that LASC has low overall incidence. It has a predilection for males, but does not demonstrate racial predominance. LASC tends to present with stage IV disease, with distant metastasis noted in approximately one in 10 cases. Overall prognosis is poor, with a median survival under 3 years. LEVEL OF EVIDENCE: 4.
Authors: Fernando López; Michelle D Williams; Antonio Cardesa; Jennifer L Hunt; Primož Strojan; Alessandra Rinaldo; Iain J Nixon; Juan P Rodrigo; Nabil F Saba; William M Mendenhall; Miquel Quer; Carlos Suárez; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2017-03-31 Impact factor: 2.503